Prior authorization
What are the Qulipta prior authorization requirements?
Note: The passages are from the QULIPTA prior authorization guide (US-QLP-250340, July 2025) that the downloadable resources page links.
How should a Qulipta PA request for continuing therapy be filed?
Note: The passage is from the QULIPTA prior authorization guide (US-QLP-250340, July 2025) that the downloadable resources page links.
Does Qulipta require step therapy?
Note: The QULIPTA prior authorization guide (US-QLP-250340, July 2025) that the downloadable resources page links states that 98% of nationally commercially insured lives are covered, and its pages 1 and 2 state the share covered with zero steps as 64% (page 1) and 62% (page 2), all with MMIT data as of December 2024. The figures quoted from the access and coverage page give 98% and 64% for 2026 (data as of January 2024 and August 2026); the page was captured on November 14, 2026. The step therapy examples are from page 5 of that guide.
What are common PA denial reasons in the Qulipta prior authorization guide?
Note: The passages are from the QULIPTA prior authorization guide (US-QLP-250340, July 2025) that the downloadable resources page links. The guide cites AbbVie data on file (its reference 1) for the denial reasons and does not state that they are specific to QULIPTA.